Categories: News

CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 9:20 a.m. Pacific Time (PT).

A live webcast of the presentation will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com

Staff

Recent Posts

Dräger PSS® AirBoss SCBA Now Available for Purchase in North America

Now Available for Purchase, AirBoss Delivers an NFPA 1970:2025 SCBA Built for the Way American…

5 hours ago

Greenway Health® Named Most Improved Physician Practice Solution 2026 by KLAS Research

KLAS recognition highlights Greenway's momentum in modernizing physician practice technologyTAMPA, Fla., Feb. 5, 2026 /PRNewswire/…

5 hours ago

Huckleberry Launches Berry: Specialized AI that Brings Family Context Front and Center

While AI booms, Berry delivers quiet confidence to parents by pairing each child's unique logged…

5 hours ago

AI Lab Goodfire Raises $150M at $1.25B Valuation to Design Models with Interpretability

SAN FRANCISCO, Feb. 5, 2026 /PRNewswire/ -- Today, Goodfire—the AI research lab using interpretability to…

5 hours ago

Nanorobotics Market worth $4.52 billion by 2032 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Feb. 5, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the global nanorobotics market…

5 hours ago

Vidle.com and LaborEdge Announce Strategic Integration to Streamline Healthcare Staffing Recruitment

Integration Delivers Faster Hiring, Qualified Candidates, and Zero Posting Fees for Healthcare Staffing AgenciesDELRAY BEACH,…

5 hours ago